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Abstract Obstetric complications play a role in the
pathophysiology of schizophrenia. However, the biological
consequences during neurodevelopment until adulthood are
unknown. Microarrays have been used for expression
proﬁling in four brain regions of a rat model of neonatal
hypoxia as a common factor of obstetric complications.
Animals were repeatedly exposed to chronic hypoxia from
postnatal (PD) day 4 through day 8 and killed at the age of
150 days. Additional groups of rats were treated with
clozapine from PD 120–150. Self-spotted chips containing
340 cDNAs related to the glutamate system (‘‘glutamate
chips’’) were used. The data show differential (up and
down) regulations of numerous genes in frontal (FR),
temporal (TE) and parietal cortex (PAR), and in caudate
putamen (CPU), but evidently many more genes are
upregulated in frontal and temporal cortex, whereas in
parietal cortex the majority of genes are downregulated.
Because of their primary presynaptic occurrence, ﬁve dif-
ferentially expressed genes (CPX1, NPY, NRXN1, SNAP-
25, and STX1A) have been selected for comparisons with
clozapine-treated animals by qRT-PCR. Complexin 1 is
upregulated in FR and TE cortex but unchanged in PAR by
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DOI 10.1007/s00406-010-0159-1hypoxic treatment. Clozapine downregulates it in FR but
upregulates it in PAR cortex. Similarly, syntaxin 1A was
upregulated in FR, but downregulated in TE and unchan-
ged in PAR cortex, whereas clozapine downregulated it in
FR but upregulated it in PAR cortex. Hence, hypoxia alters
gene expression regionally speciﬁc, which is in agreement
with reports on differentially expressed presynaptic genes
in schizophrenia. Chronic clozapine treatment may con-
tribute to normalize synaptic connectivity.
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Introduction
In addition to genetic predisposition, the neurodevelop-
mental hypothesis of schizophrenia includes a number of
environmental factors like obstetric and birth complica-
tions with ensuing consequences on the pathophysiology of
the disease. Hence, the risk of schizophrenia increases with
the number and severity of hypoxia-associated obstetric
complications [5, 6, 22]. However, the pathogenetic
implications of obstetric complications are unclear. The
neurodevelopmental hypothesis of schizophrenia suggests
that the onset of abnormal brain development and neuro-
pathology occurs perinatally, whereas symptoms of the
disease appear in early adulthood [32].
Schizophrenia patients show deﬁcits in attention and
processing of sensory information. A reliable test of sen-
sorimotor gating in vertebrates is prepulse inhibition (PPI)
of the acoustic startle reﬂex, which is disrupted in
schizophrenia patients and restored by antipsychotics,
mainly clozapine [2]. Several cortical brain regions and
striatum are involved in PPI-modulating circuitry [30]. We
previously reported on a PPI deﬁcit in rats exposed to
neonatal hypoxia appearing only during adulthood. This
deﬁcit was prevented and restored after chronic clozapine
treatment [12].
In our animal model of chronic neonatal hypoxia, rats
exhibited increased gene expression of the N-methyl-D-
aspartate (NMDA) receptor subunit NR1 in hippocampal
and cortical subregions [28], which suggests an involve-
ment of the NMDA receptor in the pathophysiology of
hypoxia-induced alterations. In schizophrenia, there is
indeed strong support for disturbances of the glutamatergic
and gamma-amino-butyric acid (GABA)ergic microcir-
cuitry, mainly affecting the expression of presynaptic
vesicle proteins including synaptosome-associated protein
25 (SNAP-25) and syntaxin, which form the soluble
N-fethylmaleimide-sensitive factor attachment protein
receptor (SNARE) complex [9, 10, 15, 20, 29]. Complexin
(CPX) 1 and complexin 2 operate in synaptic vesicle
exocytosis by stabilizing the SNARE complex [4]. Neu-
ropeptide Y (NPY) and neurexins (NRXN) play a role in
cell adhesion and are hypothesized to play a role in the
pathophysiology of schizophrenia [14, 20, 23, 26].
There is only little information about the inﬂuence of
antipsychotic treatment on gene expression, as has been
shown for NPY and CPX in normal rats [8, 16]. Thus, the
present study investigates on the impact of neonatal
hypoxia and long-term treatment with the antipsychotic
clozapine on the expression of presynaptic genes in dif-
ferent cortical and subcortical brain regions in an animal
model. Furthermore, correlations between differentially
expressed genes and PPI deﬁcits have been evaluated.
Materials and methods
Animals
A total of 12 Sprague–Dawley rats (Animal Facility,
Department of Animal Physiology, University of Tu ¨bin-
gen) were used for the experiments. The rats were housed
in groups of 3 animals under a 12-h light/dark cycle with
food and drinking water available ad libitum. The experi-
ments were carried out in accordance with the international
ethical guidelines for the care and use of laboratory animals
for experiments (declaration of Helsinki, NIH guidelines)
and were approved by the local animal care committee
(Regierungspra ¨sidium Tu ¨bingen, ZP 3/02).
Neonatal hypoxia
Chronic hypoxia (11% O2, 89% N2) was imposed from
postnatal day (PD) 4–8 on six animal pups and their
mothers by placing them in an air-tight plastic chamber for
a period of 6 h per day. The six other pups were subjected
to identical handling conditions and were placed in iden-
tical chambers but with regular oxygen concentrations
(21% O2 = normoxia) [12, 28].
Clozapine treatment
Between PD 120 and PD 150, half of the rats were being
orally treated over a period of 4 weeks with 45 mg/kg/day
clozapine (Novartis Pharma AG, Basel, Switzerland) [12].
Test on prepulse inhibition and tissue preparation
The startle magnitude was measured as described in [12].
Since a deﬁcit in prepulse inhibition had been shown to
surface on postnatal days 120 and 150, animals were killed
at postnatal day 150. Brains were removed and immersed
in -78C cold isopentane and stored at -80C until further
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used to excise respective brain regions according to the
atlas of Paxinos and Watson [25] using a micropunching
tool. Resultant, cylindrical tissue blocks were collected on
dry ice and stored at -80C until further processing.
Molecular investigations
RNA isolation and reverse transcription
One milliliter of Trizol was added to excised tissue, and
tissue was homogenized by 30 strokes of trituration. After
addition of 200 ul chloroform, the solution was transferred
to Phase-Lock tubes (Eppendorf) for phase separation.
Aqueous supernatants were puriﬁed and concentrated by
RNeasy mini columns (Qiagen). Quality control was per-
formed by OD measurements in a NanoDrop ND-1000
spectrophotometer (260/280 nm[1.8) and by electropho-
retic separation using an Agilent 2100 Bioanalyzer (R.I.N.
values[7.0).
Reverse transcription of puriﬁed total RNA was carried
out using oligo-dT primers with T7 promoter sequence and
Superscript II (Invitrogen).
In vitro transcription and labeling
Reverse-transcribed cDNAs were treated with RNAse and
with DNA polymerase to obtain double-stranded DNA.
Puriﬁed DNA was used for ampliﬁcation reactions using
RNAMaxx High Yield Transcription Kit (Stratagene) with
T7 polymerase. Typically, this in vitro transcription
resulted in 40- to 50-fold ampliﬁcation of mRNA/cDNA.
Subsequently, cRNA was reverse-transcribed. Labeled
DNA was puriﬁed and dried.
Preparation of DNA (‘‘glutamate’’) Chips
The chips represent a hypothesis driven selection of 340
cDNA sequences of genes related to glutamatergic and
GABAergic neurotransmission and synaptic vesicle
proteins (Online Resource 1a–f), obtained from clones
purchased from Deutschen Ressourcenzentrum fu ¨r
Genomfoschung (RZPD, Berlin). The cDNA-inserts of
bacterial clones were PCR-ampliﬁed directly from aliquots
of bacterial cultures grown overnight (LB medium, con-
taining antibiotic selection). After electrophoretic quality
control, PCR mixtures were dried, resuspended in betaine-
containing spotting buffer [7], and spotted on amino silane
slides (Nexterion, PeqLab), using a MicroGrid II Arrayer.
Each DNA was double-spotted, and each array was spotted
three times on the same slide. The following control DNAs
were used: salmon sperm DNA, human COT-1 DNA, 4
Arabidopsis thaliana DNAs (for spike-ins), spotting buffer,
water, and a series of DNAs derived from artiﬁcial genes
(library of random external controls = LOREC) [19].
Altogether, a chip contained 4,608 spots, including
markers at the array corners to facilitate ﬁnding the correct
orientation after scanning.
After spotting, DNAs were UV-cross-linked with a
radiation of 250 mJ/cm
2. Then, they were baked at 80C
for 2 h and stored at RT.
Hybridization and scanning of slides
Spotted slides were sequentially washed in 1% SDS solution
in distilled water, immersed in 95C distilled water, and
incubatedin55Cprehybridizationsolutionfor45 min.Then,
they were washed in distilled water, in isopropanol (20 s,
each),anddriedbyastreamofnitrogenorair.Hybridizations
were done in SlideHyb Glass Array Hybridization buffer #1
(Ambion) overnight at 56C. All subsequent washing steps at
increasing stringency were performed in the dark.
Scanning was carried out in a Packard ScanArray 5,000
scanner. Each slide was scanned twice at laser strengths of
90 and 100% to obtain a larger spectrum of ﬂuorescence
intensities.
Data processing
Data quality was assessed by a number of procedures,
including visual inspection of intensities, MA-plots, and
correlation analysis of replicates. Within-array normaliza-
tion was performed according to locally weighted scatter-
plot smoothing (LOESS) method [34]. Only rank-invariant
probes were used for model generation during this proce-
dure [27]. For between-array normalization, scaling [34]
was used. After assessing normal distribution of replicate
spots using the Kolmogorov–Smirnov test, replicates were
pooled by their arithmetic means. To identify differentially
expressed genes, two-tailed t-tests and the RankProduct
(RP) [3] method were used. The false discovery rate (FDR)
method was employed to avoid accumulation of alpha-
error. Corrected P-values\0.05 were considered signiﬁ-
cant. To limit the number of differentially expressed genes,
only those were used which were found by both t-test and
RP methods. Finally, to proﬁle overall regulation, only
genes that were differentially regulated in at least two
regions were selected for further analyses.
Quantitative real-time PCR (qRT-PCR)
Quantitative RT-PCR was carried out in 384-well plates in
an ABI Prism 7900 HT Fast Real-Time PCR cycler
(Applied Biosystems, Foster City, Ca., USA). The primer
pairs used for the respective genes are listed in Table 1.
Beta actin was used as a reference (‘‘house-keeping’’) gene.
Eur Arch Psychiatry Clin Neurosci (2010) 260 (Suppl 2):S81–S89 S83
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Microarray experiments
After statistical evaluations of the 768 genes spotted on the
glass slides by Students t tests, many of them turned out to
be signiﬁcantly regulated.
Table 2 provides an overview of differentially expressed
genes in frontal (FR), parietal (PAR), and temporal (TE)
cortex as well as in caudate putamen (CPU). At ﬁrst sight,
there are apparently large regional differences in terms of
up- or downregulation, i.e. many more genes are upregu-
lated in FR [44 vs. 4 (ratio11)] and in TE [51 vs. 22 (ratio
2.32)] compared with PAR [10 vs. 33 (ratio 0.3)]. A more
balanced situation seems to occur in CPU.
Clozapine treatment and qRT-PCR results
To obtain a clearer picture, the focus was laid upon genes
primarilybeingexpressedpresynaptically.Thosewerefurther
investigated by qRT-PCR in the four brain regions in norm-
oxic and hypoxic animals treated with clozapine (Table 3).
Evidently, CPX1 is upregulated in frontal and temporal
cortex as well as in caudate putamen, but not in parietal
cortex in hypoxic animals (Table 2). Treatment with clo-
zapine resulted in an upregulation also in parietal cortex.
NPY was upregulated by hypoxia in frontal but downreg-
ulated in temporal cortex. Neurexin1 was upregulated in
both frontal cortex and CPU in hypoxic animals. SNAP25
was also upregulated in frontal cortex but downregulated in
CPU. Additionally, it was upregulated in temporal cortex.
Another counterregulation was observed with syntaxin1A
in frontal and temporal cortex (Table 2). Interestingly, in
parietal cortex, where hypoxia had no effect, STX1A was
upregulated by clozapine (Table 3).
Discussion
Complexin1
Upregulation of CPX1 upon postnatal hypoxia in frontal,
temporal cortex, and CPU has not been reported yet
(Fig. 1). In the light that clozapine additionally upregu-
lated the gene in parietal cortex, it may be assumed that
hypoxia-induced upregulation may be a compensatory
mechanism to ensure proper vesicular transmitter release.
Associations of complexins with schizophrenia have been
repeatedly reported [9, 10, 13]. A recent report comes to
the conclusion that complexins facilitate neurotransmitter
release [33]. Speciﬁcally, it has been suggested that
CPX1 downregulation during perinatal hypoxia in
GABAergic neurons facilitates glutamate release and loss
of overstimulated neurons—which subsequently results in
reduced glutamatergic projections [24]. The upregulation
of CPX1 in parietal cortex by clozapine is supported by
the ﬁndings of Eastwood [8]. Our results showing the
very strong correlation of CPX1 with PPI in hypoxia-
treated animals (Table 4) support the view that this gene/
protein is a key player in the development of Schizo-
phrenia-like symptoms.
Neurexin1
Neurexins and neuroligins are emerging as central orga-
nizing molecules for excitatory glutamatergic and inhibi-
tory GABAergic synapses. They function as cell adhesion
molecules, bridging the synaptic cleft. Neurexin 1beta and
neuroligin normally form trans-synaptic complexes [1].
Finally, there is a recent report showing that disruption of
the neurexin 1 gene is associated with schizophrenia [26].
Preconditioningischemiacandownregulatetheincreased
neurexin–neuroligin1–PSD-95 interaction induced by
ischemia injury and exerts a neuroprotective effect. These
resultsindicatethattheneurexin-neuroligin1isanimportant
signaling module in hypoxic injury and a novel possible
target in therapeutics of brain ischemia [21].
SNAP25
Recent genetic studies implicate alterations in SNAP-25
gene structure, expression, and/or function in contributing
directly to neuropsychiatric and neurological disorders.
Protein-by-protein analyses indicated a signiﬁcant reduc-
tion in SNAP-25 immunoreactivity in the schizophrenia
non-suicide group [11, 15].
Table 1 Primers used in
qRT-PCR
Sequences reading from 50 -end
Gene Forward primer Reverse primer
CPLX1 GCAGGGCATACGAGATAAGT TGGTGGGGTCAGTGATGGCAGTA
NPY CGCTCTGCGACACTACAT CTCAGGGCTGGATCTCTTG
NRXN1 AGGGCGTCAGCTCACAATCTTCAA TCTGCCGAGCCTGGGTATGGT
SNAP25 AGTGGCGTTTGCTGAATGAC TGCTGGTATGACTTAATCTTGACA
STX1A TGTCCCGAAAGTTTGTG GCGTTCTCGGTAGTCT
S84 Eur Arch Psychiatry Clin Neurosci (2010) 260 (Suppl 2):S81–S89
123T
a
b
l
e
2
D
i
f
f
e
r
e
n
t
i
a
l
l
y
e
x
p
r
e
s
s
e
d
g
e
n
e
s
i
n
s
o
m
e
r
e
g
i
o
n
s
o
f
n
o
r
m
o
x
i
c
a
n
d
h
y
p
o
x
i
c
r
a
t
b
r
a
i
n
s
C
P
U
F
R
P
A
R
T
E
G
e
n
e
l
i
s
t
t
-
t
e
s
t
f
d
r
c
o
r
r
e
c
t
i
o
n
G
e
n
e
l
i
s
t
t
-
t
e
s
t
f
d
r
c
o
r
r
e
c
t
i
o
n
G
e
n
e
l
i
s
t
t
-
t
e
s
t
f
d
r
c
o
r
r
e
c
t
i
o
n
G
e
n
e
l
i
s
t
t
-
t
e
s
t
f
d
r
c
o
r
r
e
c
t
i
o
n
T
h
e
f
a
c
t
o
r
‘
‘
h
y
p
o
x
i
a
’
’
r
e
g
u
l
a
t
e
d
t
h
e
f
o
l
l
o
w
i
n
g
g
e
n
e
s
i
n
c
o
m
p
a
r
i
s
o
n
w
i
t
h
‘
‘
n
o
r
m
o
x
i
a
’
’
T
h
e
f
a
c
t
o
r
‘
‘
h
y
p
o
x
i
a
’
’
r
e
g
u
l
a
t
e
d
t
h
e
f
o
l
l
o
w
i
n
g
g
e
n
e
s
i
n
c
o
m
p
a
r
i
s
o
n
w
i
t
h
‘
‘
n
o
r
m
o
x
i
a
’
’
T
h
e
f
a
c
t
o
r
‘
‘
h
y
p
o
x
i
a
’
’
r
e
g
u
l
a
t
e
d
t
h
e
f
o
l
l
o
w
i
n
g
g
e
n
e
s
i
n
c
o
m
p
a
r
i
s
o
n
w
i
t
h
‘
‘
n
o
r
m
o
x
i
a
’
’
T
h
e
f
a
c
t
o
r
‘
‘
h
y
p
o
x
i
a
’
’
r
e
g
u
l
a
t
e
d
t
h
e
f
o
l
l
o
w
i
n
g
g
e
n
e
s
i
n
c
o
m
p
a
r
i
s
o
n
w
i
t
h
‘
‘
n
o
r
m
o
x
i
a
’
’
U
P
D
O
W
N
U
P
D
O
W
N
U
P
D
O
W
N
U
P
D
O
W
N
A
T
F
2
A
T
F
2
C
A
P
N
2
A
D
C
Y
3
A
T
F
4
A
U
R
K
B
C
A
P
O
N
A
D
C
Y
6
A
T
P
2
A
2
C
A
L
M
2
C
A
S
K
A
T
P
2
A
2
C
P
X
1
C
A
P
2
E
A
A
T
3
B
D
N
F
C
P
X
2
C
A
P
N
8
G
A
B
B
R
1
B
N
P
I
G
A
P
4
3
C
P
X
1
G
A
P
D
H
C
A
P
N
2
G
A
P
D
H
D
E
A
D
B
O
X
G
N
A
1
2
C
A
P
N
6
G
A
T
A
4
D
L
G
A
P
2
L
O
C
2
9
4
6
7
9
C
A
S
Q
2
G
R
M
2
D
U
S
P
1
L
O
C
3
6
2
7
0
4
C
P
X
1
I
T
P
R
1
F
Y
N
M
A
P
K
3
D
A
T
1
M
A
R
K
1
G
A
P
D
H
P
I
P
S
E
A
A
T
3
M
P
P
S
7
G
N
A
O
P
L
D
2
E
R
K
7
M
Y
D
1
1
6
M
A
P
K
1
4
P
L
E
K
H
C
1
G
A
B
R
G
3
N
M
_
0
1
7
2
6
1
M
A
P
K
3
P
O
U
3
F
4
G
A
D
6
7
N
O
S
2
M
R
P
S
7
P
P
P
1
R
1
4
A
G
A
D
D
4
5
A
N
R
X
N
1
N
E
L
L
2
P
P
P
2
R
2
C
G
A
P
4
3
P
K
N
1
N
P
Y
P
P
P
5
C
G
A
T
A
4
P
L
D
1
N
O
S
2
-
1
1
4
9
P
R
E
F
O
L
D
I
N
5
G
N
A
O
P
L
E
K
H
C
1
N
R
X
N
1
P
R
K
C
Z
G
P
S
M
1
P
P
M
1
B
P
A
C
S
I
N
2
P
T
P
R
A
G
R
M
8
P
P
P
1
C
C
P
I
M
3
P
T
P
R
R
I
D
3
P
P
K
C
C
P
L
A
T
R
A
B
1
4
I
T
P
R
3
P
T
P
4
A
1
P
P
P
1
R
1
4
B
R
A
B
3
A
L
O
C
2
9
4
6
7
9
P
T
P
R
A
P
P
P
1
R
1
4
C
R
A
B
3
B
L
O
C
3
6
2
7
0
4
P
T
P
R
N
P
T
P
4
A
2
R
N
.
2
5
0
4
5
M
G
C
1
0
5
7
6
2
P
T
P
R
N
2
P
T
P
R
D
R
N
.
2
8
2
8
4
N
P
Y
R
A
B
1
0
P
T
P
R
N
S
H
A
N
K
1
N
R
2
F
2
R
N
.
2
8
2
8
4
P
T
P
R
N
2
S
L
C
2
A
1
N
R
X
N
3
S
A
C
M
1
L
R
A
B
3
A
S
L
C
6
A
1
2
N
U
P
5
4
S
L
C
1
A
3
S
L
C
1
A
3
S
L
K
P
I
P
S
Eur Arch Psychiatry Clin Neurosci (2010) 260 (Suppl 2):S81–S89 S85
123T
a
b
l
e
2
c
o
n
t
i
n
u
e
d
C
P
U
F
R
P
A
R
T
E
G
e
n
e
l
i
s
t
t
-
t
e
s
t
f
d
r
c
o
r
r
e
c
t
i
o
n
G
e
n
e
l
i
s
t
t
-
t
e
s
t
f
d
r
c
o
r
r
e
c
t
i
o
n
G
e
n
e
l
i
s
t
t
-
t
e
s
t
f
d
r
c
o
r
r
e
c
t
i
o
n
G
e
n
e
l
i
s
t
t
-
t
e
s
t
f
d
r
c
o
r
r
e
c
t
i
o
n
T
h
e
f
a
c
t
o
r
‘
‘
h
y
p
o
x
i
a
’
’
r
e
g
u
l
a
t
e
d
t
h
e
f
o
l
l
o
w
i
n
g
g
e
n
e
s
i
n
c
o
m
p
a
r
i
s
o
n
w
i
t
h
‘
‘
n
o
r
m
o
x
i
a
’
’
T
h
e
f
a
c
t
o
r
‘
‘
h
y
p
o
x
i
a
’
’
r
e
g
u
l
a
t
e
d
t
h
e
f
o
l
l
o
w
i
n
g
g
e
n
e
s
i
n
c
o
m
p
a
r
i
s
o
n
w
i
t
h
‘
‘
n
o
r
m
o
x
i
a
’
’
T
h
e
f
a
c
t
o
r
‘
‘
h
y
p
o
x
i
a
’
’
r
e
g
u
l
a
t
e
d
t
h
e
f
o
l
l
o
w
i
n
g
g
e
n
e
s
i
n
c
o
m
p
a
r
i
s
o
n
w
i
t
h
‘
‘
n
o
r
m
o
x
i
a
’
’
T
h
e
f
a
c
t
o
r
‘
‘
h
y
p
o
x
i
a
’
’
r
e
g
u
l
a
t
e
d
t
h
e
f
o
l
l
o
w
i
n
g
g
e
n
e
s
i
n
c
o
m
p
a
r
i
s
o
n
w
i
t
h
‘
‘
n
o
r
m
o
x
i
a
’
’
U
P
D
O
W
N
U
P
D
O
W
N
U
P
D
O
W
N
U
P
D
O
W
N
S
L
C
1
A
3
S
L
C
6
A
1
2
S
R
C
P
L
D
2
S
L
C
1
A
6
S
N
A
P
2
5
S
T
A
T
3
P
N
O
C
S
L
C
3
2
A
1
S
O
D
1
S
Y
T
1
-
1
5
1
1
P
P
M
1
G
S
N
A
P
2
5
S
Q
S
T
M
1
T
R
A
N
S
C
.
L
O
C
U
S
P
P
P
1
R
1
0
S
T
A
T
3
S
R
C
P
P
P
2
R
2
C
S
Y
N
1
S
T
K
3
9
P
P
P
2
R
5
B
V
A
M
P
2
S
T
X
1
A
P
P
P
4
R
1
T
R
A
N
S
C
.
L
O
C
U
S
P
P
P
5
C
P
R
K
C
H
P
R
K
C
Z
R
A
B
1
0
R
G
S
3
R
N
.
1
3
7
8
1
3
R
N
.
1
5
9
2
6
R
N
.
7
3
8
9
S
L
C
1
A
6
S
L
C
3
2
A
1
S
L
C
6
A
1
2
S
M
A
G
P
S
N
A
P
2
5
S
P
1
S
Q
S
T
M
1
S
T
A
T
3
S
T
K
6
S
T
X
1
A
S
Y
N
1
S
Y
N
2
T
C
F
1
2
V
A
M
P
1
M
a
n
y
m
o
r
e
g
e
n
e
s
a
r
e
u
p
r
e
g
u
l
a
t
e
d
i
n
f
r
o
n
t
a
l
(
F
R
)
a
n
d
t
e
m
p
o
r
a
l
(
T
E
)
c
o
r
t
e
x
c
o
m
p
a
r
e
d
w
i
t
h
p
a
r
i
e
t
a
l
(
P
A
R
)
c
o
r
t
e
x
S86 Eur Arch Psychiatry Clin Neurosci (2010) 260 (Suppl 2):S81–S89
123In another study, however, there were no differences in
the immunoreactivity of proteins measured in schizo-
phrenic patients. Apparently prefrontal cortical dysfunc-
tion in schizophrenia may exist without gross changes in
the abundance of many synaptic proteins [13].
There were signiﬁcant decreases in tissue levels of these
proteins in prefrontal cortex of schizophrenic patients rela-
tive to controls, whereas the mRNAs encoding these pro-
teins were not decreased [18]. Normal levels of SNAP-25
Table 3 ‘‘Clozapine’’-induced effects in normoxic and hypoxic
animals (empty = no effect)
Normoxic Hypoxic
Region Gen Reg.-
Dir.
P-value Region Gen Reg.-
Dir.
P-value
CPU CPX1 CPU CPX1 up 0.026
FR CPX1 down 0.043 FR CPX1
PAR CPX1 PAR CPX1 up 0.012
TE CPX1 TE CPX1
CPU NPY CPU NPY
FR NPY FR NPY
TE NPY TE NPY
CPU NRXN1 CPU NPY
FR NRXN1 FR NRXN1
PAR NRXN1 PAR NRXN1
TE NRXN1 TE NRXN1
CPU SNAP25 CPU NRXN1
FR SNAP25 FR SNAP25
PAR SNAP25 PAR SNAP25
TE SNAP25 TE SNAP25
FR STX1A down 0.015 FR SNAP25
PAR STX1A up 0.048 PAR STX1A up 0.002
TE STX1A TE STX1A
Fig. 1 Hypoxia- and clozapine-mediated differential regulation of
presynaptic transcripts in some rat brain regions. Triple arrows :
hypoxia : chip results; dotted arrows : clozapine : qRT-PCR results
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123are noted in schizophrenia patients in Brodman area 17,
decreased levels in areas 10 and 20, and an elevated level
in area 9 [31].
In comparison with our results (Fig. 1), those ﬁndings
strongly support the notion that regionally distinct
expressions prevail and have always to be taken into
consideration.
NPY
Regionally different gene expression of NPY is observed
also in our report (Fig. 1). Patients with schizophrenia
showed deﬁcits in NPY mRNAs [14, 23]. Olanzapine and
clozapine administration acutely decreased NPY mRNA
levels in the nucleus accumbens, striatum, and anterior
cingulate cortex of rats [16, 20]. The proportion of NPY
neurons in the upper cortical layers was low, but it was
high in the deep white matter in the disorganized and
paranoid form [17].
Syntaxin 1
This presynaptic protein is another good example for
regionally different gene expression. It is upregulated in FR
but downregulated in TE, whereas there is no change in
CPU and PAR by hypoxia treatment. Clozapine upregu-
lates its expression in PAR but downregulates it in FR
(Fig. 1). From literature reports, we know that there were
signiﬁcant negative correlations between age and mRNA
levels of syntaxin 1A in schizophrenic patients. They were
increased in the younger (58–79 years) subgroup of
schizophrenic patients—which suggests that they reﬂect
overall neurodevelopmental abnormalities in synaptic
connectivity in the temporal cortex of schizophrenic
patients [29].
Conclusions
Presynaptic proteins have been reported to be differentially
regulated in schizophrenia. In our animal model of peri-
natal hypoxia, alterations in presynaptic genes in adulthood
during the time period of behavioral deﬁcits have been
shown and may be involved in the pathophysiology leading
to schizophrenia symptoms. However, we focused only on
genes of the glutamatergic system, and all conclusions are
limited to this domain. Our results reveal that chronic
clozapine treatment may differentially inﬂuence gene
expression and in this way contribute to the treatment of
symptoms. Animal models of risk factors of schizophrenia
are warranted to elucidate disease mechanisms and speciﬁc
effects of antipsychotic treatment in disease states.
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